Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
Drug results: 1
| nerandomilast | Nerandomilast is a selective inhibitor of phosphodiesterase 4 (PDE4) with preferential inhibition of the PDE4B isoenzyme over PDE4A, C and D. There is a 9-fold selectivity over PDE4D, 24-fold selectivity over PDE4A and 870-fold selectivity over PDE4C based on in vitro data. At the recommended doses, inhibition of PDE4B and weaker inhibition of PDE4D can be expected. PDE4 hydrolyses and inactivates cyclic adenosine monophosphate (cAMP). Nerandomilast exerts both anti-fibrotic and immunomodulatory effects as preferential PDE4B inhibition elevates intracellular cAMP levels and reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, which are overexpressed in fibrotic lung disease. |
|








Citing DrugCentral © 2026.
License